CSIMarket
 
Vtv Therapeutics Inc   (VTVT)
Other Ticker:  
 
 
Price: $18.0000 $0.95 5.572%
Day's High: $18.4994 Week Perf: 19.84 %
Day's Low: $ 16.57 30 Day Perf: 85.76 %
Volume (M): 21 52 Wk High: $ 39.60
Volume (M$): $ 376 52 Wk Avg: $21.12
Open: $16.98 52 Wk Low: $7.38



 Market Capitalization (Millions $) 38
 Shares Outstanding (Millions) 2
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -26
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Vtv Therapeutics Inc
Vtv Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of innovative small molecule drugs to treat various diseases. The company is known for its expertise in target-based drug discovery and employs a unique approach to drug development, utilizing cutting-edge technologies and collaborative research partnerships. Vtv Therapeutics aims to bring novel therapeutics to the market that can significantly improve patient outcomes and address unmet medical needs.


   Company Address: 3980 Premier Dr High Point 27265 NC
   Company Phone Number: 841-0300   Stock Exchange / Ticker: NASDAQ VTVT
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Vtv Therapeutics Inc

Major Pharmaceutical Preparations Companies Show Consistent Efforts in Q4 20232.

Vtv Therapeutics Inc is a clinical stage biopharmaceutical company that is focused on the development of an oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). The company recently reported its financial results for the fourth quarter and year ended December 31, 2023, and provided an update on recent corporate developments.
In terms of financial performance, for the fiscal period ending December 31, 2023, VTVT decreased its loss per share to $-1.54 per share, compared to $-1.88 per share in the previous year. Earnings per share also improved from $-3.20 per share to $-1.54 per share. The revenue remained unchanged at $0.00 million, compared to $0.01 million in the same reporting period a year prior. The company reported a net shortfall of $-4.441 million, an improvement from a deficit of $-6.090 million in the previous year. The net loss for the fiscal year was $-25.97 million, with revenue for the 12 months totaling $0.00 million.
Vtv Therapeutics Inc has also made significant advancements in its clinical trials. The company recently submitted the study protocol for its first Phase 3 trial to the U.S. Food and Drug Administration (FDA). This trial aims to evaluate the safety and efficacy of their lead candidate, cadisegliatin (TTP399), as an adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D) in adults. T1D is a chronic autoimmune disease characterized by the body's inability to produce insulin, resulting in high blood sugar levels. Insulin therapy is currently the standard treatment for T1D; however, vTv Therapeutics is striving to revolutionize the field by introducing an innovative adjunctive therapy that could potentially improve the lives of millions of patients.
In terms of stock performance, Vtv Therapeutics Inc shares have recorded a solid gain of 9.32% over the past 7 days and are up by 39.07% in 2024. However, the shares are currently trading on the NASDAQ at -29.9% below its 52-week average.

Product Service News

vTv Therapeutics Takes a Major Step Towards the Treatment of Type 1 Diabetes with Cadisegliatin as FDA Receives Phase 3 Study Protocol Submission

Published Mon, Mar 4 2024 1:01 PM UTC

Sophisticated vTv Therapeutics Inc., a renowned clinical stage biopharmaceutical company with a focus on the development of innovative treatments, has recently submitted the study protocol for its first Phase 3 trial to the U.S. Food and Drug Administration (FDA). This trial aims to evaluate the safety and efficacy of their lead candidate, cadisegliatin (TTP399), as an adjun...

Financing Agreement

vTv Therapeutics Secures $51 Million Funding to Advance Cadisegliatin and Tackle Type 1 Diabetes

Published Wed, Feb 28 2024 1:00 PM UTC



vTv Therapeutics, a renowned pharmaceutical company focused on developing innovative treatments for chronic diseases, has recently announced a major milestone in its journey to combat type 1 diabetes (T1D). The company has successfully raised $51 million through a private placement from prominent healthcare-focused institutional investors and the JDRF T1D Fund.

Vtv Therapeutics Inc

Explosive Growth Unleashed: Company Surprises Shareholders with Stunning $-5.368M Rise in Latest Fiscal Period

During the past 5 trading days, Vtv Therapeutics Inc stock has experienced a significant drop of -7.33%, further contributing to a year-to-date performance decline of -51.11%. The stock is currently trading 1.1% above its 52-week low.
Vtv Therapeutics Inc operates in the Major Pharmaceutical Preparations industry, alongside larger companies in the market. While the focus is often on these major players, it is important to keep an eye on lesser-known businesses as well. VTVT, a clinical stage biopharmaceutical company specializing in the development of cadisegliatin (TTP399) as a supplementary therapy to insulin for type 1 diabetes (T1D), recently reported its earnings for the third quarter of 2023.

Shares

vTv Therapeutics Inc (Nasdaq: VTVT), a clinical stage biopharmaceutical company specializing in the development of cadisegliatin (TTP399) as a supplementary therapy to insulin for type 1 diabetes (T1D), recently announced a major milestone The company has successfully sold all of its common stock in Reneo Pharmaceuticals, Inc,

Published Wed, Nov 1 2023 12:01 PM UTC

vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company specializing in the development of cadisegliatin (TTP399) as a supplementary therapy to insulin for type 1 diabetes (T1D), recently announced a major milestone. The company has successfully sold all of its common stock in Reneo Pharmaceuticals, Inc., generating an impressive $4.4 million in proc...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com